

## Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is re-ranked each year and is calculated under a modified capitalization-weighted methodology. Additionally, the NBI forms the basis for a number of Exchange Traded Funds (ETFs). More information about the NBI, including eligibility criteria, can be found at <https://indexes.nasdaqomx.com/Index/Overview/NBI>.

### About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a registration-enabling Phase 2 clinical trial for EBV-positive (EBV<sup>+</sup>) lymphoma and a Phase 1b/2 trial in patients with EBV<sup>+</sup> nasopharyngeal carcinoma and other EBV<sup>+</sup> solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit [www.viracta.com](http://www.viracta.com).

### Investor Relations Contact:

Ashleigh Barreto  
Head of Investor Relations & Corporate Communication  
Viracta Therapeutics, Inc.  
[abarreto@viracta.com](mailto:abarreto@viracta.com)

SOURCE Viracta Therapeutics, Inc.

---

<https://viracta.investorroom.com/2021-12-16-Viracta-Therapeutics-to-be-Added-to-the-Nasdaq-Biotechnology-Index>